PharmAbcine Newsletter - 2Q22
2Q22 Updates

PharmAbcine was very active in expanding its global network in the second quarter of 2022. In June, the Company participated in both ‘Jefferies Global Healthcare Conference 2022”, a global healthcare investment forum in New York, and ‘BIO International Convention (BIO USA) 2022’, an annual biotechnology and pharmaceutical science conference that took place in San Diego, California. The receding cases of COVID-19 infection have allowed this year’s events to be held in-person, through which we were able to engage in meetings with global companies in much more depth.


We had significant progresses in our R&D pipeline developments as well. For example, we strengthened our Scientific Advisory Board with the appointment of Dr. Quan Dong Nguyen from Stanford University, a world-renowned expert in ophthalmology. His clinical development expertise and insights are providing tremendous support for the clinical development of PMC-403, our novel TIE2 agonistic antibody candidate.


Recent R&D updates are as follows.


With regards to the olinvacimab, our lead pipeline, the Phase II olinvacimab-pembrolizumab combo study is currently ongoing and actively recruiting patients in Australia. The two patients, who have been receiving olinvacimab under compassionate use in the Phase Ib olinvacimab-pembrolizumab combo study in mTNBC, are still receiving the treatment. The clinical report for the Phase Ib trial is expected to be available in 3Q22.


We also presented the updated nonclinical data of PMC-309, one of the Company’s first immuno-oncology assets, at AACR (American Association for Cancer Research) 2022. The new data shows that PMC-309 can activate not just adaptive immunity like anti-PD-1/L1 and anti-CTLA4 agents do, but also activate innate immunity through monocyte activation. This distinctive mode of action allows PMC-309 to be used for cancer patients who show low or no response to the current standard of care.


All our preclinical assets (PMC-403, PMC-309, and PMC-402) are currently IND-ready. None of them showed serious adverse events in GLP-Toxicology studies. The Company plans to submit IND applications for these assets in the second half of this year.

Events and accomplishments 

AACR 2022 (April 8-13, 2022)

PMC-309 (Click here for the full poster)

  • PMC-309 has a unique mode of action that indirectly activates T cells by inhibiting MDSCs and M2 macrophages, which suppress T cells.
  • The distinct mode of action allows it to be used both in monotherapy and combination with other drugs to treat patients who show low or no response to the marketed drugs.

PMC-403 (Click here for the full poster)

  • The leaky and disorganized blood vessel in the tumor microenvironment causes insufficient delivery of drug and immune cells to the tumor cells and lowers clinical efficacy of radiation therapy.
  • PMC-403 stabilizes leaky and disorganized blood vessel and improves drug and immune cell delivery to the TME. This can result in effective tumor growth inhibition even with smaller dosage of radiation and reduce the cases and severity of adverse events.

Jefferies Global Healthcare Conference 2022, New York (June 8-10, 2022)

About the conference
  • Jefferies Group is the largest independent, global, full-service investment banking firm headquartered in the U.S and a leader in providing insight, expertise and execution to investors, companies and governments.
  • Its annual event showcases nearly 500 public and private companies in biopharmaceutical, life sciences, healthcare, and medical technology sector and over 3,000 leading executives, private investors, and venture capitalists.


  • Yoo, CEO of PharmAbcine, met with several investors to discuss potential investment opportunities and expanded the Company’s global network.

BIO International Convention 2022, San Diego (June 13-16, 2022)

About the conference
  • The BIO International Convention is a global annual event where over 15,000 biotechnology and pharma leaders come together to form intensive network to discover new opportunities and promising partnerships.
    • Yoo and the Business Development team participated in Merck reception and one-on-one partnering meetings with 36 companies (including several top 10 pharmaceutical companies) to discuss potential licensing deals.
    • Most of the companies at the partnering meetings showed great interest in both PMC-309 and PMC-403.
    • On the last day of the event, Dr. Yoo presented the current and future R&D plans to the participants from other biotechs and investment institutions.
    • After the event, the Company scheduled multiple follow-up meetings with nearly 30 companies to discuss potential partnership in more detail.
    This document has been prepared by PharmAbcine Co., Ltd. (hereafter, the “Company”) to provide information on presentations to institutional investors regarding the proposed. “Forecast information” in this document is information that has not been subject to an individual verification. The forecast is related to future events, not the past, which means the Company’s future management status and financial performance. In terms of expression, it includes words such as “forecast,” “prospect,” “plan,” “expectation,” and “(E).”The above “forecast information” is influenced by future changes in management environment and inherently subject to uncertainties that may result in significant discrepancies between actual future performance and what is stated or implied in “forecast information. “Furthermore, the prospect is based on the presentation date, considering the present market conditions and the direction of the Company's management. Please be aware that changes may occur without notice due to changes in the market environment and strategies. Please note that the Company and its employees are not liable for any loss or damage incurred in connection with the use of this document, including negligence or otherwise. This document does not constitute any solicitation for offers, sales, trading, or subscription of stock, and any part of this document cannot be the basis for the relevant contracts, arrangements, or investment decisions. Please note that this material may be used for Preprofit purposes without content modification(however, source representation is required), and unauthorized distribution and reproduction of materials with modified content without prior approval of the Company may result in legal sanctions.
    Contact Info

    IR/PR: Sookyoung Shin, Head 
    T: +82.42.863.2017

    IR/PR: Sungjun Park, Associate 
    T: +82.42.863.2017 

    2F, Research Building 2, 70, Yuseong-daero 1689 beon-gil, Yuseong-gu, Daejeon, Republic of Korea